MX2016000384A - Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. - Google Patents

Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.

Info

Publication number
MX2016000384A
MX2016000384A MX2016000384A MX2016000384A MX2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A
Authority
MX
Mexico
Prior art keywords
vegf antagonist
treating
chorioretinal neovascular
child
permeability disorders
Prior art date
Application number
MX2016000384A
Other languages
English (en)
Spanish (es)
Inventor
Sergey Aksenov
Gabriela Burian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016000384A publication Critical patent/MX2016000384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2016000384A 2013-07-11 2014-07-09 Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. MX2016000384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845064P 2013-07-11 2013-07-11
PCT/IB2014/062978 WO2015004616A1 (en) 2013-07-11 2014-07-09 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

Publications (1)

Publication Number Publication Date
MX2016000384A true MX2016000384A (es) 2016-04-29

Family

ID=51211282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000384A MX2016000384A (es) 2013-07-11 2014-07-09 Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.

Country Status (11)

Country Link
US (2) US20160168240A1 (enExample)
EP (1) EP3019526A1 (enExample)
JP (1) JP2016528202A (enExample)
KR (1) KR20160029794A (enExample)
CN (1) CN105377891A (enExample)
AU (2) AU2014288837A1 (enExample)
BR (1) BR112016000177A2 (enExample)
CA (1) CA2917807A1 (enExample)
MX (1) MX2016000384A (enExample)
RU (1) RU2676274C2 (enExample)
WO (1) WO2015004616A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2015173260A1 (en) * 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
US20180326126A1 (en) * 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN109310756B (zh) * 2016-05-13 2022-06-28 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3573641A4 (en) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
BR112019023061A2 (pt) * 2017-05-01 2020-06-09 Ojai Retinal Tech Llc processo para prevenir ou tratar miopia
AU2018370135A1 (en) * 2017-11-16 2020-06-04 Iveric Bio, Inc. A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
RU2762991C1 (ru) * 2021-09-06 2021-12-24 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4761750A1 (en) * 2023-08-17 2026-06-24 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema
CN118085112B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗多个vegf家族蛋白的融合蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2716110A1 (en) * 2008-02-21 2009-08-27 Tim Mcnamara Ophthalmic nsaids as adjuvants
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
NZ592591A (en) * 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
JP5988584B2 (ja) * 2008-12-16 2016-09-07 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． 眼の状態に関する光線力学的療法
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Also Published As

Publication number Publication date
KR20160029794A (ko) 2016-03-15
RU2676274C2 (ru) 2018-12-27
CN105377891A (zh) 2016-03-02
CA2917807A1 (en) 2015-01-15
EP3019526A1 (en) 2016-05-18
US20160168240A1 (en) 2016-06-16
RU2016104397A (ru) 2017-08-16
BR112016000177A2 (pt) 2017-12-12
JP2016528202A (ja) 2016-09-15
WO2015004616A1 (en) 2015-01-15
RU2016104397A3 (enExample) 2018-05-31
US20180194835A1 (en) 2018-07-12
AU2017203923B2 (en) 2018-10-18
AU2017203923A1 (en) 2017-07-06
AU2014288837A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
MX2016000385A (es) Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.
JP2012046524A5 (enExample)
MX2017005875A (es) Metodos para tratar enfermedades oculares.
BR112016000177A2 (pt) usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MY199027A (en) Method for treating or preventing ophthalmological conditions
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
HK1209341A1 (zh) 與治療柏金遜症相關之運動與動作障礙副作用之治療
MX374612B (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
PL3370693T3 (pl) Ulepszone preparaty lewosimendanu do podawania dożylnego w postaci roztworów do wlewów lub wstrzykiwań i koncentratu do wlewów
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
MX2022006770A (es) Dispersiones solidas de bendamustina e infusion continua.
MX2020004106A (es) Metodo de tratamiento de trastornos neurodegenerativos.
GB201518170D0 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
AR102494A1 (es) Métodos para tratar enfermedades oculares
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
PH12014502497A1 (en) New treatments of hepatitis c virus infection
WO2014149998A8 (en) Systemic administration of androgen in treating dry eye syndrome